Beta-NGF

Beta-NGF Informations sur la molécule

Nom anglais	Nerve growth factor	Nombre de médicaments commercialisés	0
Nombre de médicaments cliniques	14	Alias de la cible	Nerve Growth Factor
Phase de R&D la plus avancée	NDA/BLA

Nom anglais	Nerve growth factor
Alias de la cible	Nerve Growth Factor
Nombre de médicaments commercialisés	0
Nombre de médicaments cliniques	14
Phase de R&D la plus avancée	NDA/BLA

Beta-NGF Liste de produits

Attribut
Protein (2)
Bibliothèque de produits
En ligne (2)
Espèces
Human (1)Mouse (1)
Étiquette
Tag Free (2)
Marqueur
Unconjugated (2)

Numéro de produit	Espèces	Système d'expression	Description du produit	Structure protéique	Pureté	Caractéristiques	Pré-commande/Commande
BEF-H5214	Human	HEK293	Human Beta-NGF Protein, premium grade				Ajouter au panier
BEF-M5213	Mouse	HEK293	Mouse Beta-NGF Protein, Tag Free, low endotoxin (MALS verified)				Ajouter au panier

Quantité totale2

Beta-NGFContexte de la molécule

Nerve growth factor beta (beta-NGF) is a neurotrophic factor that plays critical role in the development and maintenance of sensory and sympathetic neurons. The active form of human beta-NGF is is a noncovalently disulfide-linked homodimer, which is secreted and signals through the low affinity nerve growth factor receptor (LNGFR) and the tropomyosin receptor kinase A (TrkA) to activate PI3K, Ras, and PLC signaling pathways.

Beta-NGFAlias de la molécule

NGF,NGFB,Beta-NGF,HSAN5,MGC161426,MGC161428

Informations sur les médicaments cliniques

Nom anglais	Code de recherche	Phase de R&D	Entreprise	Indication	Essai clinique
RGN-259	RGN-457; RGN-352; RGN-259; RGN-137; Tβ4; TB4; GBT-101; GBT-201; Thymosin beta 4-16-38; TB4 16-38; Thymosin beta4; Thymosin B4; Fx peptide	Phase 3 Clinical	National Institutes Of Health	Diabetes Mellitus; Dry Eye Syndromes; Epidermolysis Bullosa; Epidermolysis Bullosa Dystrophica; Epidermolysis Bullosa, Junctional; Graft vs Host Disease; Keratitis; Myocardial Infarction; Myocardial Ischemia; Pressure Ulcer; Sjogren's Syndrome; ST Elevation Myocardial Infarction; Varicose Ulcer; Xerophthalmia	Details
Fasinumab	SAR-164877; MT-5547; R-475; REGN-475	Phase 3 Clinical	Regeneron Pharmaceuticals Inc	Abdominal Pain; Back Pain; Low Back Pain; Osteoarthritis; Osteoarthritis, Hip; Osteoarthritis, Knee; Sciatica	Details
SSS-40	SSS-40; SSS-40-anti-NGF Ab; SSS40 anti-NGF Ab	Phase 2 Clinical	3sbio Inc	Bone Neoplasms; Cancer Pain; Osteoarthritis	Details
SHR-2017	SHR-2017; SHR2017	Phase 2 Clinical	Suzhou Suncadia Biopharmaceuticals Co Ltd	Bone metastases; Multiple Myeloma; Osteoporosis; Solid tumours	Details
Antibodies to humanized nerve growth factor(Shenyang Sunshine Pharmaceutical)		Phase 2 Clinical	Shenyang Sunshine Pharmaceutical Co Ltd	Bone metastases; Cancer Pain	Details
EP-9001A	EP-9001A	Phase 2 Clinical	Chengdu Youluo Biotechnology Co Ltd	Bone metastases; Cancer Pain; Pain	Details
DS-002	DS-002	Phase 2 Clinical	Dartsbio Pharmaceuticals Ltd	Cancer Pain; Pain	Details
Atinumab	NG-101; ATI-355	Phase 2 Clinical	Novartis Pharma Ag	Diabetic Gastroparesis; Gastroparesis; Spinal Cord Injuries	Details
Luvagrobart	AK-115	Phase 1 Clinical		Cancer Pain; Pain	Details
4B03-04	4B03-04	Phase 1 Clinical	Fubei Biomedical Technology (Beijing) Co Ltd	Osteoarthritis	Details
DS-010	DS010; DS-010	Phase 1 Clinical	Dartsbio Pharmaceuticals Ltd	Cachexia	Details
TNM-009	TNM-009; TNM009	Phase 1 Clinical	Zhuhai Trinomab Pharmaceutical Co Ltd	Cancer Pain; Pain	Details
SMR-7694	SMR-7694; SMR7694	Phase 1 Clinical	Sinobioway Biomedicine Co Ltd	Osteoarthritis	Details
Neuroregenerative agents (iNtRON Biotechnology)		Clinical	Intron Biotechnology	Nervous System Diseases	Details